Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 10 Similar Profiles
Therapeutics Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Pancreatic Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Sarcoma Medicine & Life Sciences
Radiotherapy Medicine & Life Sciences
Survival Medicine & Life Sciences
Fluorouracil Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 1997 2021

Research Output 1988 2017

  • 4108 Citations
  • 37 Scopus h-Index
  • 116 Article
  • 9 Review article
  • 2 Comment/debate
  • 2 Letter
4 Citations

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Bendell, J. C., Javle, M., Bekaii-Saab, T. S., Finn, R. S., Wainberg, Z. A., Laheru, D. A., Weekes, C. D., Tan, B. R., Khan, G. N., Zalupski, M. M., Infante, J. R., Jones, S., Papadopoulos, K. P., Tolcher, A. W., Chavira, R. E., Christy-Bittel, J. L., Barrett, E. & Patnaik, A. Feb 28 2017 In : British Journal of Cancer. 116, 5, p. 575-583 9 p.

Research output: Research - peer-reviewArticle

MEK162
Maximum Tolerated Dose
Biliary Tract Neoplasms
Neoplasms
Pharmacokinetics

Definitive Chemoradiation with Full-dose Gemcitabine for Unresectable Pancreatic Cancer: Efficacy of Involved-Field Radiotherapy

Zhou, J., Fang, C. X., Shen, J., Schipper, M. J., Zalupski, M. M., Minter, R. M., Simeone, D. M., Hart, D., Eagle, T., Kimmel, G. W., Vainshtein, J., Lawrence, T. S. & Feng, M. 2017 In : American Journal of Clinical Oncology: Cancer Clinical Trials. 40, 5, p. 517-522 6 p.

Research output: Research - peer-reviewArticle

gemcitabine
Pancreatic Neoplasms
Radiotherapy
Recurrence
Survival

Integrative clinical genomics of metastatic cancer

Robinson, D. R. , Wu, Y. M. , Lonigro, R. J. , Vats, P. , Cobain, E. , Everett, J. , Cao, X. , Rabban, E. , Kumar-Sinha, C. , Raymond, V. , Schuetze, S. , Alva, A. , Siddiqui, J. , Chugh, R. , Worden, F. , Zalupski, M. M. , Innis, J. , Mody, R. J. , Tomlins, S. A. , Lucas, D. & 13 others Baker, L. H., Ramnath, N., Schott, A. F., Hayes, D. F., Vijai, J., Offit, K., Stoffel, E. M., Roberts, J. S., Smith, D. C., Kunju, L. P., Talpaz, M., Cieślik, M. & Chinnaiyan, A. M. Aug 17 2017 In : Nature. 548, 7667, p. 297-303 7 p.

Research output: Research - peer-reviewArticle

Genomics
Neoplasms
Exome
RNA Sequence Analysis
Tumor Microenvironment
1 Citations

A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer

Zhen, D. B., Griffith, K. A., Ruch, J. M., Camphausen, K., Savage, J. E., Kim, E. J., Sahai, V., Simeone, D. M. & Zalupski, M. M. Dec 1 2016 In : Investigational New Drugs. 34, 6, p. 733-739 7 p.

Research output: Research - peer-reviewArticle

gemcitabine
Pancreatic Neoplasms
cabozantinib
Maximum Tolerated Dose
Adenocarcinoma
Adjuvant Chemotherapy
Sarcoma
Cysteine
Blood Proteins
Survival